McKesson Sees Cash Flow Upside To Slow Growth, Inventory Management
McKesson sees a bright spot from the overall slowdown in the pharmaceutical market and the prevalence of inventory management arrangements: enhanced cash flow
More from Archive
More from Pink Sheet
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.